Pharmacokinetics, activity, and safety of ODM-201 in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: An open-label phase I trial with long-term extension.

被引：0
|
作者：
Massard, Christophe
Penttinen, Heidi
Bono, Petri
Vjaters, Egils
Lietuvietis, Vilnis
Tammela, Teuvo L. J.
Vuorela, Annamari
Nykanen, Pirjo
Pohjanjousi, Pasi
Fizazi, Karim
机构：
[1] Univ Paris 11, Inst Gustave Roussy, Villejuif, France
[2] Univ Helsinki, Cent Hosp, Ctr Canc, Helsinki, Finland
[3] P Stradins Clin Univ Hosp, Riga, Latvia
[4] Riga East Univ Hosp, Riga, Latvia
[5] Tampere Univ Hosp, Tampere, Finland
[6] Orion Corp Orion Pharma, Espoo, Finland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.230
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
230
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study
    Massard, Christophe
    Penttinen, Heidi M.
    Vjaters, Egils
    Bono, Petri
    Lietuvietis, Vilnis
    Tammela, Teuvo L.
    Vuorela, Annamari
    Nykanen, Pirjo
    Pohjanjousi, Pasi
    Snapir, Amir
    Fizazi, Karim
    EUROPEAN UROLOGY, 2016, 69 (05) : 834 - 840
  • [2] A study of two ODM-201 formulations with a safety and tolerability extension phase in patients with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC)
    Massard, Christophe
    Tammela, Teuvo L. J.
    Vjaters, Egils
    Lietuvietis, Vilnis
    Bono, Petri
    Penttinen, Heidi
    Nykanen, Pirjo
    Snapir, Amir
    Mattila, Leena
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [3] An open-label, phase I/II safety, pharmacokinetic, and proof-of concept study of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (CRPC)
    Fizazi, K.
    Bono, P.
    Jones, R. H.
    Kataja, V.
    James, N.
    Garcia, J.
    Protheroe, A.
    Vuorela, A.
    Mattila, L.
    Mustonen, M. V. J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S680 - S680
  • [4] Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
    Fizazi, Karim
    Massard, Christophe
    Bono, Petri
    Jones, Robert
    Kataja, Vesa
    James, Nicholas
    Garcia, Jorge A.
    Protheroe, Andrew
    Tammela, Teuvo L.
    Elliott, Tony
    Mattila, Leena
    Aspegren, John
    Vuorela, Annamari
    Langmuir, Peter
    Mustonen, Mika
    LANCET ONCOLOGY, 2014, 15 (09): : 975 - 985
  • [5] Re: Activity and Safety of ODM-201 in Patients with Progressive Metastatic Castration-resistant Prostate Cancer (ARADES): An Open-label Phase 1 Dose-escalation and Randomised Phase 2 Dose Expansion Trial
    Bjartell, Anders
    EUROPEAN UROLOGY, 2015, 67 (02) : 348 - 349
  • [6] A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naive patients with metastatic castration-resistant prostate cancer
    Aggarwal, Rahul Raj
    Weinberg, Vivian K.
    Ryan, Charles J.
    Harzstark, Andrea Lynne
    Bryce, Alan Haruo
    Derleth, Christina Louise
    Lowe, Kimberly
    Small, Eric Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Bone and soft tissue response from a phase I/II study with ODM-201 in metastatic castration-resistant prostate cancer (mCRPC)
    Garcia, Jorge A.
    Kataja, Vesa V.
    James, Nicholas David
    Jones, Robert Hugh
    Protheroe, Andrew
    Massard, Christophe
    Mattila, Leena
    Mustonen, Mika V. J.
    Aspegren, John
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [8] ARAMIS trial: Efficacy and safety of ODM-201 in men with high-risk nonmetastatic castration-resistant prostate cancer
    Suzuki, Kazuhiro
    Kuss, Iris
    Smith, Matthew R.
    Fizazi, Karim
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] ARAMIS trial: Efficacy and safety phase 3 trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).
    Fizazi, Karim
    Shore, Neal D.
    Tammela, Teuvo L. J.
    Sarapohja, Toni
    Vuorela, Annamari
    Kuss, Iris
    Snapir, Amir
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] ODM-201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: Preclinical and phase I data
    Fizazi, Karim
    Massard, Christophe
    James, Nicholas David
    Culine, Stephane
    Jones, Robert Hugh
    Oksala, Riikka
    Moilanen, Anu
    Aho, Eija
    Ravanti, Laura
    Kallio, Pekka
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345